Scientists and doctors remain divided on the targeted antibody drugs that slow down the early stages of Alzheimer’s ...

Two new drugs for Alzheimer’s have been rejected for use on the NHS. They slow progression of the disease, but they can have serious side-effects. – What are the medicines? Donanemab and lecanemab are ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages ... Last year, NHS England published a briefing paper suggesting the cost of bringing the drugs to the health ...

Lantern Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer Contacts Investor Relations [email protected] ...

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said.

DALLAS, January 27, 2025--Lantern Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer ...

Lantern Pharma Inc., an artificial intelligence company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today ...